New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing promising results in patients with advanced solid tumors, particularly ovarian cancer. The data were presented during the European Society of Medical Oncology (ESMO) Congress 2024 and later updated during an Incyte investor event, emphasising the potential of […]